HRP20230463T1 - Stabilna anti-ifnar1 formulacija - Google Patents

Stabilna anti-ifnar1 formulacija Download PDF

Info

Publication number
HRP20230463T1
HRP20230463T1 HRP20230463TT HRP20230463T HRP20230463T1 HR P20230463 T1 HRP20230463 T1 HR P20230463T1 HR P20230463T T HRP20230463T T HR P20230463TT HR P20230463 T HRP20230463 T HR P20230463T HR P20230463 T1 HRP20230463 T1 HR P20230463T1
Authority
HR
Croatia
Prior art keywords
buffer
formulation
histidine
formulation according
lysine
Prior art date
Application number
HRP20230463TT
Other languages
English (en)
Croatian (hr)
Inventor
Roberto Depaz
Natalie DEJESUS
Jared BEE
Original Assignee
Astrazeneca Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=58052002&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HRP20230463(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astrazeneca Ab filed Critical Astrazeneca Ab
Publication of HRP20230463T1 publication Critical patent/HRP20230463T1/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2866—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against receptors for cytokines, lymphokines, interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39591—Stabilisation, fragmentation
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12P—FERMENTATION OR ENZYME-USING PROCESSES TO SYNTHESISE A DESIRED CHEMICAL COMPOUND OR COMPOSITION OR TO SEPARATE OPTICAL ISOMERS FROM A RACEMIC MIXTURE
    • C12P21/00—Preparation of peptides or proteins
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Mycology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Transplantation (AREA)
HRP20230463TT 2015-08-19 2016-08-18 Stabilna anti-ifnar1 formulacija HRP20230463T1 (hr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201562207164P 2015-08-19 2015-08-19
EP20174805.0A EP3769781B1 (en) 2015-08-19 2016-08-18 Stable anti-ifnar1 formulation

Publications (1)

Publication Number Publication Date
HRP20230463T1 true HRP20230463T1 (hr) 2023-07-21

Family

ID=58052002

Family Applications (2)

Application Number Title Priority Date Filing Date
HRP20230463TT HRP20230463T1 (hr) 2015-08-19 2016-08-18 Stabilna anti-ifnar1 formulacija
HRP20201297TT HRP20201297T1 (hr) 2015-08-19 2016-08-18 Stabilna formulacija anti-ifnar1

Family Applications After (1)

Application Number Title Priority Date Filing Date
HRP20201297TT HRP20201297T1 (hr) 2015-08-19 2016-08-18 Stabilna formulacija anti-ifnar1

Country Status (23)

Country Link
US (1) US10125195B2 (https=)
EP (3) EP3337502B1 (https=)
JP (4) JP6720293B2 (https=)
KR (4) KR102669174B1 (https=)
CN (1) CN107921109B (https=)
AU (3) AU2016308262C1 (https=)
CA (1) CA2995222C (https=)
CY (2) CY1123657T1 (https=)
DK (2) DK3337502T3 (https=)
ES (2) ES2818229T3 (https=)
FI (1) FI3769781T3 (https=)
HR (2) HRP20230463T1 (https=)
HU (2) HUE061985T2 (https=)
IL (1) IL257279B2 (https=)
LT (2) LT3337502T (https=)
PL (2) PL3769781T3 (https=)
PT (2) PT3337502T (https=)
RS (2) RS64263B1 (https=)
RU (1) RU2731737C2 (https=)
SG (1) SG10202106970XA (https=)
SI (2) SI3769781T1 (https=)
SM (2) SMT202000483T1 (https=)
WO (1) WO2017031288A1 (https=)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2995222C (en) 2015-08-19 2021-07-13 Medimmune, Llc Stable anti-ifnar1 formulation
GB201719447D0 (en) 2017-11-23 2018-01-10 Ucb Biopharma Sprl Pharmaceutical composition
US20200061015A1 (en) 2018-08-23 2020-02-27 Janssen Biotech, Inc. Lipase Degradation Resistant Surfactants for Use in Large Molecule Therapeutic Formulations
MY204234A (en) 2018-08-27 2024-08-16 Regeneron Pharma Use of raman spectroscopy in downstream purification
KR102735988B1 (ko) 2019-02-18 2024-12-03 일라이 릴리 앤드 캄파니 치료 항체 제제
CN110179746A (zh) * 2019-05-17 2019-08-30 通化东宝生物科技有限公司 一种稳定的苏金单抗注射剂及其制备方法
KR102766960B1 (ko) * 2019-11-11 2025-02-11 아스트라제네카 아베 전신성 홍반성 루푸스에서 i형 인터페론 억제
CN115667309A (zh) * 2020-05-29 2023-01-31 阿斯利康(瑞典)有限公司 使用i型干扰素信号传导的抑制剂治疗心血管代谢疾病
IL299215A (en) 2020-06-25 2023-02-01 Medimmune Ltd Prevention of axonal damage through binding of an antibody to amyloid beta 1-42
TW202237647A (zh) 2020-10-08 2022-10-01 瑞典商阿斯特捷利康公司 狼瘡發作之治療
AU2021404495A1 (en) * 2020-12-17 2023-07-27 Astrazeneca Ab Anti-il5r antibody formulations
PT4192882T (pt) 2021-04-23 2025-05-02 Astrazeneca Ab Tratamento de nefrite lúpica com anticorpo anifrolumab de recetor inf anti-tipo i
HRP20231255T1 (hr) * 2021-04-23 2024-02-02 Astrazeneca Ab Režim doziranja anti-ifnar1 za potkožnu injekciju
CN117157099A (zh) * 2021-04-23 2023-12-01 阿斯利康(瑞典)有限公司 用于皮下注射的抗ifnar1给药方案
BR112023021868A2 (pt) 2021-04-23 2023-12-19 Astrazeneca Ab Tratamento de lúpus eritematoso cutâneo
US20250002591A1 (en) 2021-05-12 2025-01-02 Astrazeneca Ab Inhibitor of type 1 interferon receptor steroid sparing in systemic lupus erythermatosus patients
CN113521276B (zh) * 2021-07-13 2022-04-12 江苏荃信生物医药股份有限公司 包含抗人干扰素α受体1(IFNAR1)单克隆抗体的液体制剂
WO2023284073A1 (zh) * 2021-07-13 2023-01-19 江苏荃信生物医药股份有限公司 降低单克隆抗体生产中宿主细胞蛋白含量的亲和纯化方法、抗人ifnar1单克隆抗体浓缩溶液的制备方法以及液体制剂
CN113527490B (zh) * 2021-07-13 2022-03-01 江苏荃信生物医药股份有限公司 一种抗人ifnar1单克隆抗体浓缩溶液的制备方法
CA3226744A1 (en) 2021-07-27 2023-02-02 Astrazeneca Ab Treatment of lupus
WO2023057369A2 (en) 2021-10-04 2023-04-13 Astrazeneca Ab Treatment of lupus
EP4422674A4 (en) * 2021-10-29 2025-09-17 Intas Pharmaceuticals Ltd Stable lyophilized formulation of an anti-alpha 4beta7 antibody
WO2023155902A1 (en) * 2022-02-18 2023-08-24 Chongqing Mingdao Haoyue Biotechnology Co., Ltd. Intranasal formulations and anti-sars-cov-2-spike protein antibodies
IN202221038828A (https=) * 2022-07-06 2024-01-12
JP2025533978A (ja) 2022-10-13 2025-10-09 アストラゼネカ・アクチエボラーグ ループスの治療
CN121127499A (zh) 2023-05-19 2025-12-12 阿斯利康(瑞典)有限公司 狼疮的治疗
WO2025022280A1 (en) 2023-07-21 2025-01-30 Astrazeneca Ab Treatment of neurodegenerative diseases
GB202315831D0 (en) 2023-10-16 2023-11-29 Astrazeneca Ab Treatment of skin disease
GB202402824D0 (en) 2024-02-28 2024-04-10 Astrazeneca Ab Treatment of chronic kidney disease

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US6713609B1 (en) * 1996-07-16 2004-03-30 Genentech, Inc. Monoclonal antibodies to type I interferon receptor
HUE035082T2 (en) * 2004-06-21 2018-05-02 Squibb & Sons Llc Interferon alpha receptor 1 antibodies and their use
JO3000B1 (ar) * 2004-10-20 2016-09-05 Genentech Inc مركبات أجسام مضادة .
JP2010512356A (ja) * 2006-12-11 2010-04-22 エフ．ホフマン−ラ ロシュ アーゲー 非経口ａベータ抗体製剤
EP2170268A2 (en) * 2007-06-25 2010-04-07 Amgen, Inc. Compositions of specific binding agents to hepatocyte growth factor
US9308257B2 (en) * 2007-11-28 2016-04-12 Medimmune, Llc Protein formulation
HRP20160855T1 (hr) 2008-02-08 2016-09-23 Medimmune, Llc Anti-ifnar1 protutijela sa smanjenim afinitetom fc liganda
JP5933975B2 (ja) * 2008-11-12 2016-06-15 メディミューン，エルエルシー 抗体製剤
US20110152188A1 (en) * 2009-12-23 2011-06-23 Hanns-Christian Mahler Pharmaceutical compositions of igf/i proteins
US20110223208A1 (en) * 2010-03-09 2011-09-15 Beth Hill Non-Aqueous High Concentration Reduced Viscosity Suspension Formulations
US20150010634A1 (en) * 2011-10-12 2015-01-08 Ascendis Pharma Ophthamology Division A/S Prevention and treatment of ocular conditions
AU2012328524B2 (en) * 2011-10-28 2017-05-18 Excelse Bio, Inc. Protein formulations containing amino acids
US8883979B2 (en) 2012-08-31 2014-11-11 Bayer Healthcare Llc Anti-prolactin receptor antibody formulations
US9592297B2 (en) 2012-08-31 2017-03-14 Bayer Healthcare Llc Antibody and protein formulations
US20150239970A1 (en) * 2012-10-25 2015-08-27 Medimmune, Llc Stable, Low Viscosity Antibody Formulation
AU2014265624B2 (en) * 2013-05-15 2019-09-12 Medimmune Limited Purification of recombinantly produced polypeptides
IL312865B2 (en) * 2013-09-11 2025-06-01 Eagle Biologics Inc Liquid protein formulations containing viscosity-lowering agents
EP3062814A1 (en) 2013-10-29 2016-09-07 Albumedix A/S Antibody composition
RU2017107847A (ru) 2014-09-03 2018-10-03 Медиммун Лимитед Стабильный состав на основе антитела к il-4r-альфа
JP2018500380A (ja) 2014-12-31 2018-01-11 ノベルメド セラピューティクス，インコーポレーテッド アグリコシル化治療用抗体の製剤
CA2995222C (en) 2015-08-19 2021-07-13 Medimmune, Llc Stable anti-ifnar1 formulation

Also Published As

Publication number Publication date
BR112018002196A8 (pt) 2021-05-04
AU2016308262B2 (en) 2020-04-30
JP7035119B2 (ja) 2022-03-14
AU2016308262C1 (en) 2022-04-21
CN107921109B (zh) 2026-04-14
EP4233892A2 (en) 2023-08-30
PT3337502T (pt) 2020-09-23
HK1256195A1 (en) 2019-09-13
JP2020158527A (ja) 2020-10-01
IL257279A (en) 2018-03-29
BR112018002196A2 (pt) 2019-04-30
DK3769781T3 (da) 2023-06-19
KR102669174B1 (ko) 2024-06-10
AU2020203306A1 (en) 2020-06-11
DK3337502T3 (da) 2020-09-14
PL3337502T3 (pl) 2021-01-11
RU2018107725A (ru) 2019-09-19
JP2022066345A (ja) 2022-04-28
HUE061985T2 (hu) 2023-09-28
EP3337502A1 (en) 2018-06-27
JP2018523676A (ja) 2018-08-23
LT3337502T (lt) 2020-09-25
KR20200119916A (ko) 2020-10-20
EP3337502B1 (en) 2020-06-24
HRP20201297T1 (hr) 2020-11-27
ES2818229T3 (es) 2021-04-09
AU2021257915A1 (en) 2021-11-18
US10125195B2 (en) 2018-11-13
KR20220127378A (ko) 2022-09-19
JP6720293B2 (ja) 2020-07-08
IL257279B2 (en) 2023-04-01
RS60773B1 (sr) 2020-10-30
IL257279B (en) 2022-12-01
DK3769781T5 (da) 2024-08-19
SMT202000483T1 (it) 2020-11-10
AU2016308262A1 (en) 2018-03-08
LT3769781T (lt) 2023-06-12
CN107921109A (zh) 2018-04-17
PT3769781T (pt) 2023-06-19
CY1126062T1 (el) 2023-11-15
CY1123657T1 (el) 2022-03-24
HUE051862T2 (hu) 2021-03-29
RS64263B1 (sr) 2023-07-31
CA2995222A1 (en) 2017-02-23
SI3337502T1 (sl) 2020-10-30
SI3769781T1 (sl) 2023-06-30
US20170051066A1 (en) 2017-02-23
CA2995222C (en) 2021-07-13
AU2020203306B2 (en) 2021-09-09
EP3769781A1 (en) 2021-01-27
SMT202300176T1 (it) 2023-07-20
FI3769781T3 (fi) 2023-06-07
SG10202106970XA (en) 2021-07-29
EP4233892A3 (en) 2023-10-25
AU2020203306C1 (en) 2022-03-31
ES2947488T3 (es) 2023-08-10
KR20240090616A (ko) 2024-06-21
EP3337502A4 (en) 2019-01-23
JP2024161043A (ja) 2024-11-15
KR20180041173A (ko) 2018-04-23
KR102168005B1 (ko) 2020-10-21
RU2731737C2 (ru) 2020-09-08
WO2017031288A1 (en) 2017-02-23
RU2018107725A3 (https=) 2019-10-02
PL3769781T3 (pl) 2023-07-17
EP3769781B1 (en) 2023-04-19

Similar Documents

Publication Publication Date Title
HRP20230463T1 (hr) Stabilna anti-ifnar1 formulacija
CN104080441B (zh) 包括肽治疗剂和氨基酸的微针装置、制备和使用其的方法
HRP20240426T1 (hr) Stabilni tekući farmaceutski pripravak
AR092387A1 (es) Formulaciones de anticuerpo anti receptor de prolactina
HRP20210749T1 (hr) Farmaceutski pripravci koji sadrže azd9291
HRP20211371T1 (hr) Stabilne, vodene formulacije protutijela
CY1117941T1 (el) Υψηλης συγκεντρωσης φapμαkeytika σκευασματα που περιλαμβανουν το αντισωμα κatα cd20
JP2017516847A5 (https=)
JP2015134763A5 (https=)
NZ730821A (en) Stable protein solution formulation containing high concentration of an anti-vegf antibody
HRP20211899T1 (hr) Formulacija protutijela
FI3506886T3 (fi) Erittäin väkevöityjä alhaisen viskositeetin masp-2:ta estäviä vasta-aineformulaatioita, tarvikesarjoja ja menetelmiä
HRP20130109T4 (hr) Formulacije kaspofungina
HRP20201241T1 (hr) Nanosuspenzije lijeka osušene zamrzavanjem
HRP20200434T1 (hr) Stabilne vodene formulacije adalimumaba
JP2008500345A5 (https=)
FI3541366T3 (fi) Exendiinin (9-39) puskuroidut formulaatiot
JP2018523676A5 (https=)
HRP20120903T1 (hr) Tekuä†a formulacija koja sadrži visoku koncentraciju protutijela
WO2013164789A3 (en) Lyophilised and aqueous anti-cd40 antibody formulations
JP2017516848A5 (https=)
JP2019509311A5 (https=)
HRP20181226T1 (hr) Tekući farmaceutski sustav
CN101370504A (zh) 用tcm278对hiv感染进行的长期治疗
HRP20200196T1 (hr) Fiziološki balansirane injektabilne formulacije fosnetupitanta